StockData
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. (ENVB) stock

ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.41−0.03 (-2.08%)

Close on Nov 17, 2026Market cap $6.31MP/E –Yield –

Enveric Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Enveric Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$8.73M. For fiscal 2025 it was -$8.77M. The highest annual figure on record is $32.81K in fiscal 2014.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.77M–
FY2024Dec 31, 2024-$9.63M–
FY2023Dec 31, 2023-$16.45M–
FY2022Dec 31, 2022-$27.42M–
FY2021Dec 31, 2021-$64.62M–
FY2020Dec 31, 2020-$5.62M–
FY2019Dec 31, 2019-$2.30M–
FY2018Dec 31, 2018-$7.15M–
FY2017Dec 31, 2017-$10.90M–
FY2016Dec 31, 2016-$5.38M–
FY2015Dec 31, 2015-$793.98K-2519.9%
FY2014Dec 31, 2014$32.81K+20.6%
FY2013Dec 31, 2013$27.21K–
FY2012Dec 31, 2012-$22.69K–
FY2011Dec 31, 2011-$31.40K–
FY2010Dec 31, 2010-$35.88K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.03M–
Q1 FY2026Mar 31, 2026-$1.63M–
Q4 FY2025Dec 31, 2025-$2.19M–
Q3 FY2025Sep 30, 2025-$1.87M–
Q2 FY2025Jun 30, 2025-$2.52M–
Q1 FY2025Mar 31, 2025-$2.19M–
Q4 FY2024Dec 31, 2024-$3.17M–
Q3 FY2024Sep 30, 2024-$2.08M–
Q2 FY2024Jun 30, 2024-$1.90M–
Q1 FY2024Mar 31, 2024-$2.48M–
Q4 FY2023Dec 31, 2023-$2.38M–
Q3 FY2023Sep 30, 2023-$3.45M–
Q2 FY2023Jun 30, 2023-$5.76M–
Q1 FY2023Mar 31, 2023-$4.86M–
Q4 FY2022Dec 31, 2022-$12.26M–
Q3 FY2022Sep 30, 2022-$5.66M–
Q2 FY2022Jun 30, 2022-$4.71M–
Q1 FY2022Mar 31, 2022-$4.80M–
Q4 FY2021Dec 31, 2021-$50.98M–
Q3 FY2021Sep 30, 2021-$3.52M–
Q2 FY2021Jun 30, 2021-$3.36M–
Q1 FY2021Mar 31, 2021-$6.76M–
Q4 FY2020Dec 31, 2020-$3.52M-272.4%
Q3 FY2020Sep 30, 2020-$489.83K–
Q2 FY2020Jun 30, 2020-$767.51K–
Q1 FY2020Mar 31, 2020-$836.70K–
Q4 FY2019Dec 31, 2019$2.04M–
Q3 FY2019Sep 30, 2019-$1.57M-125.7%
Q2 FY2019Jun 30, 2019-$1.48M–
Q1 FY2019Mar 31, 2019-$1.30M–
Q4 FY2018Dec 31, 2018-$10.80M–
Q3 FY2018Sep 30, 2018$6.10M–
Q2 FY2018Jun 30, 2018-$1.08M–
Q1 FY2018Mar 31, 2018-$1.37M–
Q4 FY2017Dec 31, 2017-$3.21M–
Q3 FY2017Sep 30, 2017-$3.95M–
Q2 FY2017Jun 30, 2017-$3.51M–
Q1 FY2017Mar 31, 2017-$630.55K–
Q4 FY2016Dec 31, 2016-$2.17M–
Q3 FY2016Sep 30, 2016-$1.29M–

More Enveric Biosciences figures

See a number that looks wrong?